Not yet recruitingPHASE2, PHASE3NCT07463313

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

Studying Thymic carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Principal Investigator
Fan Jiang, MD, PhD
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Intervention
Cyclophosphamide, Doxorubicin, and Cisplatin (CAP)(drug)
Enrollment
116 enrolled
Eligibility
18-65 years · All sexes
Timeline
2026 – 2032

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07463313 on ClinicalTrials.gov

Other trials for Thymic carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Thymic carcinoma →

← Back to all trials